ALK and adenocarcinoma: Molecular and clinical studies of NSCLC have identified functional mutations in tyrosine kinase (TK) receptors such as anaplastic lymphoma kinase (ALK), present in ~7% of adenocarcinoma tumors that can be used in targeted therapy [4].